Quarterly report pursuant to Section 13 or 15(d)

Revenues - Percentage by Customer (Details)

v3.21.2
Revenues - Percentage by Customer (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Grifols | fostamatinib        
Disaggregation of Revenue [Line Items]        
Expected rollout term     18 months  
Sales | Customer concentration risk | ASD Healthcare and Oncology Supply        
Disaggregation of Revenue [Line Items]        
Percentage 36.00% 47.00% 13.00% 20.00%
Sales | Customer concentration risk | McKesson Specialty Care Distribution Corporation        
Disaggregation of Revenue [Line Items]        
Percentage 33.00% 41.00% 13.00% 16.00%
Sales | Customer concentration risk | Lilly        
Disaggregation of Revenue [Line Items]        
Percentage 16.00%   65.00%  
Sales | Customer concentration risk | Cardinal Healthcare        
Disaggregation of Revenue [Line Items]        
Percentage 13.00%      
Sales | Customer concentration risk | Grifols        
Disaggregation of Revenue [Line Items]        
Percentage       61.00%